<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>846</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11297681</PubmedId>
            <Abstract>The influenza virus strains A/NT/60/68 and A/PR/8/34 both have an immunodominant D(b)-restricted epitope in their nucleoprotein (NP) at amino acid residues 366-374, with two amino acid differences between the epitopes. Cross-reactive cytotoxic T lymphocytes (CTLs) were generated by priming mice with the influenza virus A/NT/60/68 NP and restimulating in vitro with influenza virus A/PR/8/34. CTLs that gave high levels of specific lysis recognized target cells infected with either strain of influenza virus with similar efficiency. Surprisingly, when target cells were infected with recombinant vaccinia viruses (VV) expressing the two different NPs, presentation of the D(b)-restricted epitope from the A/NT/60/68 NP was extremely poor, whereas presentation of the equivalent epitope from the A/PR/8/34 NP was as efficient as in influenza virus-infected cells. This difference was observed in spite of the fact that the two NP sequences show 94% identity at the amino acid sequence level. Experiments with additional cross-reactive CTL cell lines which recognized target cells less efficiently revealed a similar difference in presentation between the two NP epitopes in influenza virus-infected cells and showed a difference in the efficiency of presentation of the D(b)-restricted epitope from the two NP molecules independent of VV infection. The results show that two equivalent epitopes in highly similar proteins are processed with very different efficiency, even though they are both immunodominant epitopes. They also suggest that the previously described inhibition of antigen presentation by VV is a general, non-specific effect, which is more apparent for epitopes that are processed and presented less efficiently.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>1069-1074</ArticlePages>
            <ArticleTitle>Differential processing and presentation of the H-2D(b)-restricted epitope from two different strains of influenza virus nucleoprotein.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Potter</LastName>
                    <ForeName>Paul</ForeName>
                </Author>
                <Author>
                    <LastName>Tourdot</LastName>
                    <ForeName>Sophie</ForeName>
                </Author>
                <Author>
                    <LastName>Blanchard</LastName>
                    <ForeName>Tom</ForeName>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>Geoffrey L</ForeName>
                </Author>
                <Author>
                    <LastName>Gould</LastName>
                    <ForeName>Keith G</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Immunology, Imperial College School of Medicine (St Mary's Campus), Norfolk Place, London W2 1PG, UK1; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK2.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Epitopes, T-Lymphocyte;H-2 Antigens;Histocompatibility Antigen H-2D;Nucleoproteins;Peptide Fragments;Viral Core Proteins;nucleoprotein (366-374), influenza virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigen Presentation(immunology); Antigens, Viral(immunology); Cell Line; Cross Reactions; Epitopes, T-Lymphocyte(immunology); Female; Genetic Vectors(immunology); H-2 Antigens(immunology); Histocompatibility Antigen H-2D; Humans; Influenza A virus(immunology); Major Histocompatibility Complex(immunology); Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Nucleoproteins(immunology); Peptide Fragments(immunology); T-Lymphocytes, Cytotoxic(immunology); Vaccinia virus(immunology); Viral Core Proteins(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>82</Volume>
                <Issue>Pt 5</Issue>
                <Title>The Journal of general virology</Title>
                <Issn>0022-1317</Issn>
                <MedlineTa>J Gen Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP366-374</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASNENMETM</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>374</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC124</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 3</LocationOfData>
                <EpitopeId>4602</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>374</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This is the immunodominant epitope of NP and the sequence varies among different influenza strains.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>9161</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <IedbAccession>SRC124</IedbAccession>
                                            </Molecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Ub-Arg-NP-VAC (Influenza nucleoprotein presented by a recombinant vaccinia virus)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Internal Identifier-no external match available</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The CTL cell line used was created by i.v. injection of recombinant vaccinia virus expressing the nucleoprotein sequence from influenza virus A/NT/60/68 and splenocytes were further stimulated in vitro by splenocytes infected with influenza virues A/PR/8/34 to test the effect of vaccinia presentation of the influenza epitope.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMETM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC124</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The CTL cell line used was created by intravenous injection of recombinant vaccinia virus expressing the nucleoprotein sequence from influenza virus A/NT/60/68 and further in vitro stimulation by splenocytes infected by influenza virus A/PR/8/34 to study the effect of vaccinia presentation of influenza epitopes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP366-374</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASNENMDAM</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>374</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03467.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>384505</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 3</LocationOfData>
                <EpitopeId>4578</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>374</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This is the immunodominant epitope of NP and the sequence varies among different influenza strains.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>9162</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P03467.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>384505</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Ub-Arg-NP-VAC (Influenza nucleoprotein presented by a recombinant vaccinia virus.</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>384505</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The CTL cell line used was created by i.v. injection of recombinant vaccinia virus expressing the nucleoprotein sequence from influenza virus A/NT/60/68 and splenocytes were further stimulated in vitro by splenocytes infected with influenza virues A/PR/8/34 to test the effect of vaccinia presentation of the influenza epitope.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>L cells-Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366-374</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMDAM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03467.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>384505</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The CTL cell line used was created by intravenous injection of recombinant vaccinia virus expressing the nucleoprotein sequence from influenza virus A/NT/60/68 and further in vitro stimulation by splenocytes infected by influenza virues A/PR/8/34 to study the effect of vaccinia presentation of influenza epitopes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

